Aytu Biopharma Inc Stock Price, News & Analysis

Aytu BioPharma (NASDAQ:AYTU) announced the formation of a Scientific Advisory Board (SAB) chaired by Dr. Hal Dietz, an expert in genetic disorders. The SAB aims to guide the development of AR101 (enzastaurin), an investigational treatment for Vascular Ehlers-Danlos Syndrome (VEDS), a rare genetic condition with no approved therapies. Initial members include renowned experts from leading institutions worldwide, who will provide insights to minimize clinical risks and advance AR101's pivotal studies. The company emphasizes that strong leadership from the SAB is vital as it seeks to enhance treatment options for VEDS patients.

Aytu BioPharma (NASDAQ:AYTU) announced that its CEO Josh Disbrow will present at two investor conferences in September 2021. The first presentation is at the H. C. Wainwright 23rd Annual Global Investment Conference, available on demand starting September 13, 2021, at 7 a.m. ET. The second is a live presentation at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021, at 4:40 p.m. ET. Both presentations will be accessible on Aytu's website. Aytu specializes in therapeutics for pediatric conditions and is developing treatments for rare genetic diseases.

Aytu BioPharma announced the publication of laboratory data demonstrating that ultraviolet A (UVA) light used in its Healight technology significantly reduces cytokine release in cells infected with coronavirus. The study, published in Photodiagnosis and Photodynamics Therapy, shows that narrow band UVA therapy decreases pro-inflammatory cytokines such as IL-6 and TNF-α by over 50%. The company plans to initiate a larger Phase 2 clinical study in Europe later in 2021, aiming to further explore Healight's potential as a treatment for severe respiratory infections, including SARS-CoV-2.

Aytu BioPharma recently announced significant findings from a first-in-human clinical trial of its Healight technology, published in Advances In Therapy. The study involved five critically ill COVID-19 patients and demonstrated a substantial reduction in SARS-CoV-2 viral load, achieving log changes of -2.41 (>99%, p=0.0018) by day five and -3.2 (>99.9%, p=0.0005) by day six. WHO clinical severity scores improved by an average of 1.6 points on day 15 and 3.6 points on day 30. Importantly, no serious adverse effects were reported. Aytu plans a larger, randomized study in Europe in early 2022.

Aytu BioPharma (NASDAQ:AYTU) announced that CEO Josh Disbrow will present at two investor conferences in June 2021. The Jefferies Global Healthcare Conference will host a live virtual presentation on June 1 at 3:30 p.m. ET, which can be accessed via this link. The second presentation will be on June 23 at 12:40 p.m. ET at the Raymond James Human Health Innovations Conference. Both presentations will be available on the Aytu website and conference sites.

Aytu BioPharma closed its merger with Neos Therapeutics, creating a $100 million revenue specialty pharmaceutical company. The recent quarter saw net revenue increase to $13.5 million, driven by strong performance in both the consumer health division, which reported $8.4 million, and the Rx division, which achieved $5.1 million. However, the company reported a net loss of $25.5 million, primarily due to merger-related expenses. The company has added AR101, a late-stage pediatric asset, to its pipeline, and appointed Rich Eisenstadt as CFO to support growth.

Aytu BioPharma (AYTU) announced the publication of a study demonstrating that ultraviolet (UV) A light can enhance the expression of mitochondrial antiviral-signaling (MAVS) protein in cells. The manuscript, published in BioRxiv, suggests that UVA light elicits an antiviral effect through cell-to-cell communication, potentially offering therapeutic benefits against SARS-CoV-2 without requiring direct exposure to the light. The study highlights increased MAVS levels in human tracheal epithelial cells exposed to narrow band UVA, with significant results indicating a promising avenue for antiviral therapies.

Aytu BioPharma, Inc. (NASDAQ:AYTU) will hold a conference call on May 17, 2021, at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter ended March 31, 2021. This meeting aims to review recent accomplishments and provide insights into the company's performance. Interested parties can join the call or access the live webcast through the company’s website. Aytu specializes in novel therapeutics and consumer healthcare products, focusing on prescription treatments for pediatric conditions like ADHD.

Aytu BioPharma has secured a global license for AR101 (enzastaurin), targeting vascular Ehlers-Danlos Syndrome (vEDS), a severe genetic disorder lacking FDA-approved treatments. The company paid $1.5 million upfront, with potential milestone payments up to $67.5 million contingent on regulatory and commercial achievements. Two co-founders from Rumpus Therapeutics, Christopher Brooke and Nate Massari, are joining Aytu's executive team to lead the AR101 program. The acquisition aligns with Aytu's strategy to enhance its portfolio in pediatric specialty pharmaceuticals.